BridgeBio Oncology Therapeutics Inc. (BBOT) Stock Score, Valuation & Financial Research

BridgeBio Oncology Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for BBOT

BridgeBio Oncology Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.50. These figures are a research snapshot, not a buy or sell recommendation.

What BridgeBio Oncology Therapeutics Inc. does

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company that focuses on the research and development of novel small molecule therapeutics. As a clinical-stage entity, the company does not currently generate revenue from product sales and relies on capital raises and potential future commercialization of its pipeline candidates to fund operations.

Products and services

  • The company is developing a pipeline of small molecule inhibitors targeting RAS and PI3K malignancies, including clinical-stage candidates BBO-8520, BBO-11818, and BBO-10203.

Customer types

Patients with RAS and PI3K malignancies.

Suppliers, materials and equipment

  • Contract Research Organizations and Contract Manufacturing Organizations — The company relies on third-party contract research organizations and contract manufacturing organizations for the conduct of clinical trials and the manufacturing of drug candidates. Source

Business strengths to evaluate

  • Pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies Source

Business risks and research considerations

  • Clinical-stage company with no history of product revenue and significant operating losses Source
  • Dependence on third-party clinical trial and manufacturing partners Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

BBOT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.50
Market capitalization:
280.37M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -182.11M
Free cash flow:
USD -114.5M
Cash:
USD 54.06M
Total debt:
USD 2.51M
EPS:
USD -1232.82

What stands out

  • Free cash flow is USD -114.5M, negative for the stored period.
  • The balance sheet shows USD 54.06M of cash versus USD 2.51M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 51.55M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for BBOT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can BBOT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is BBOT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for BBOT to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of BBOT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research BBOT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.